This is a firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Stemcell Technologies Inc., a subsidiary of the Canadian biotechnology company Stemcell Technologies. The $10,820 contract is for the provision of human neutrophil isolation kits and related reagents and supplies to support an ongoing sepsis study being conducted by the NHLBI. This contract does not have a small business set-aside designation. Stemcell Technologies Inc. is a major supplier of specialized biological research products and equipment to various civilian federal health agencies, including the NIH, Centers for Disease Control and Prevention, and Food and Drug Administration. The parent company, Stemcell Technologies, holds a substantial $10 million Blanket Purchase Agreement with the NIH to facilitate the streamlined procurement of critical research materials across multiple NIH institutes and centers.
Generated 4/2/25, 10:20 AM